EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS

The aim of this study was to identify the most effective (in the clinical and pharmacoeconomic aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory to radioactive iodine in patients – residents of the Russian Federation.Materials and Methods. The b...

Full description

Bibliographic Details
Main Authors:	M. Yu. Frolov, V. A. Rogov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2017-05-01
Series:	Фармакоэкономика
Subjects:	lenvatinib sorafenib “cost-effectiveness” analysis budget impact analysis pharmacoeconomics thyroid cancer
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/177

Similar Items

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
by: Nigel Fleeman, et al.
Published: (2019-12-01)

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
by: Nigel Fleeman, et al.
Published: (2020-01-01)

Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
by: Naoki Fukuda, et al.
Published: (2021-05-01)

Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council
by: P O Rumyantsev, et al.
Published: (2016-09-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01)

SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
by: Soo Young Kim, et al.
Published: (2018-10-01)

Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer
by: Seok-Mo Kim, et al.
Published: (2020-02-01)

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2018-02-01)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
by: Yasuko Hyogo, et al.
Published: (2018-11-01)

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
by: S. Morelli, et al.
Published: (2017-07-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
by: Loredana Lorusso, et al.
Published: (2021-03-01)

A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
by: Dipasquale A, et al.
Published: (2021-04-01)

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
by: Yu-Ling Lu, et al.
Published: (2021-07-01)

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation
by: V. V. Ryazhenov, et al.
Published: (2018-11-01)

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis
by: Yu S, et al.
Published: (2019-02-01)

The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
by: P O Rumyantsev
Published: (2015-06-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Pharmacoeconomic analysis of subdermal tocilizumab in patients with rheumatoid arthritis
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
by: Ole Vincent Ancker, et al.
Published: (2017-03-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
by: Jaejun Lee, et al.
Published: (2020-12-01)

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
by: Amit Mahipal, et al.
Published: (2019-07-01)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
by: Tella SH, et al.
Published: (2019-11-01)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
by: Hui-Yao Huang, et al.
Published: (2020-11-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

Comparative pharmacoeconomic analysis of Paclical® and Taxol® in Russian Federation
by: A. E. Cheberda, et al.
Published: (2018-05-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
by: M. Yu. Fedyanin, et al.
Published: (2017-09-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Cannot write session to /tmp/vufind_sessions/sess_n92bfkrsokakm559e46l4v4mcd